TITLE

Variation in Hepatitis C services may lead to inequity of heath-care provision: a survey of the organisation and delivery of services in the United Kingdom

AUTHOR(S)
Parkes, Julie; Roderick, Paul; Bennett-Lloyd, Bethan; Rosenberg, William
PUB. DATE
January 2006
SOURCE
BMC Public Health;2006, Vol. 6, p3
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Chronic hepatitis C infection (CHC) is a major healthcare problem. Effective antiviral therapy is available. To maximise population effectiveness, co-ordinated services for detection and management of patients with CHC are required. There is a need to determine patterns of healthcare delivery to plan improvements. A study was conducted to determine workload, configuration and care processes of current UK services available to manage patients with CHC. Methods: A cross-sectional questionnaire survey of consultant members of British Association for the Study of the Liver (n = 53), Infectious Disease consultants (n = 43), and a 1 in 5 sample of Genito-Urinary Medicine (n = 48) and gastroenterologists (n = 200). Results: Response rate was 70%. 40% of respondents provided a comprehensive service (included treatment and follow-up): speciality of clinical leads identified as Hepatology (37%); Gastroenterology (47%); and Infectious Disease (16%). The estimated number of patients managed by respondents was about 23,000 with an upward trend over the previous 3 years. There was variation between comprehensive service providers, including unit size, eligibility criteria for treatment, and drug regimes. Key barriers to quality of care identified were staffing capacity, funding of treatment and patient non-attendance. Most English strategic health authorities had at least one comprehensive service provider. Conclusion: There was significant variation in all aspects of the patient pathway which may contribute to inequity of health care provision. Services need to be expanded to form geographical clinical networks, and properly resourced to ensure greater uptake and more equitable delivery of services if the future burden of chronic liver disease is to be reduced.
ACCESSION #
29362154

 

Related Articles

  • THE ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN THE DIAGNOSIS OF CHRONIC HEPATITIS C VIRUS INFECTION RELATED ARTHRITIS. Caraba, A.; Florea, Cristina; Nicoară, Diana; Şerban, Corina; Romoşan, I. // Annals of the Romanian Society for Cell Biology;2010, Vol. 15 Issue 2, p242 

    The presence of extrahepatic mani-festations is a relatively common feature in patients with chronic hepatitis C virus infection. Among them, articular in-volvement is frequent, generating many problems of diagnosis and treatment. The aim of this study was represented by the assessment of the...

  • Hepatitis C THE SILENT EPIDEMIC. Mueller, Michelle // Current Health 2;Jan2004, Vol. 30 Issue 5, p28 

    Provides information on the chronic disease hepatitis C.

  • Effects of Interferon Treatment Response on Liver Complications of Chronic Hepatitis C: 9-year Follow-Up Study. Coverdale, Shirley A.; Khan, Mahbub H.; Byth, Karen; Lin, Rita; Weltman, Martin; George, Jacob; Samarasinghe, Dev; Liddle, Christopher; Kench, James G.; Crewe, Evelyn; Farrell, Geoffrey C. // American Journal of Gastroenterology;Apr2004, Vol. 99 Issue 4, p636 

    OBJECTIVES: Fibrotic severity, biochemical indices of poor liver function, and sporadic transmission are independent predictors of liver complications among people with chronic hepatitis C. After accounting for these factors, we tested whether interferon treatment or the treatment response...

  • Natural Course of Chronic HCV and HBV Infection and Role of Alcohol in the General Population: The Dionysos Study. Bedogni, Giorgio; Miglioli, Lucia; Masutti, Flora; Ferri, Silvia; Castiglione, Anna; Lenzi, Marco; Crocè, Lory Saveria; Granito, Alessandro; Tiribelli, Claudio; Bellentani, Stefano // American Journal of Gastroenterology;Sep2008, Vol. 103 Issue 9, p2248 

    BACKGROUND: Population-based studies of the natural course of chronic viral liver disease that consider comorbidity factors are lacking. Using data from the Dionysos Study, we quantified the burden of chronic viral liver disease and the role of alcohol intake to morbidity and mortality in a...

  • HCV infection treatment: a future full of hope. Amiri, Majid; Kiahashemi, Katayoun // Gastroenterology & Hepatology from Bed to Bench;Winter2013, Vol. 6 Issue 1, p1 

    The authors discuss future of hepatitis C virus (HCV) infection treatment. HCV infection is a major public health problem worldwide and the current treatment for HCV is IFN-based, however, there is a need to develop newer agents having more efficiency and less adverse effects as compared with...

  • Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C. Gupta, Samir; Kolz, Karen; Cutler, David // European Journal of Clinical Pharmacology;Jun2011, Vol. 67 Issue 6, p591 

    Purpose: To examine the effect of pegylated interferon (PEG-IFN) alfa-2b on the activity of major drug-metabolizing enzymes. Methods: This nonrandomized, open-label, multiple-dose study examined the effects of PEG-IFN alfa-2b on the activity of CYP450 1A2, 2 C8/9, 2D6, and 3A4 enzymes and...

  • HPA warns of future burden of hepatitis C.  // Practice Nurse;8/12/2011, Vol. 41 Issue 13, p6 

    The article announces that a report from the British Health Protection Agency, available at the web site http://bit.ly/pXMeKt, has warned that some 4,200 people in England may need a liver transplant by 2020 due to hepatitis C.

  • Uncovering Glucose Abnormalities in People With Hepatitis C Infection: Should Oral Glucose Tolerance Test Become a Standard of Care? Aytaman, Ayse; McFarlane, Samy I. // American Journal of Gastroenterology;Aug2008, Vol. 103 Issue 8, p1941 

    Hepatitis C and type 2 diabetes mellitus (DM) are two rising epidemics with significant impact on each other. Hepatitis C-infected patients have a higher incidence of type 2 diabetes, and diabetic patients have a high prevalence of hepatitis C. There is mounting evidence that glucose...

  • NIH panel recommends combination HCV treatment. K.T. // American Journal of Health-System Pharmacy;7/15/2002, Vol. 59 Issue 14, p1320 

    Presents key issues on the treatment of hepatitis C addressed during a panel discussion on June 10-12, 2002, at the U.S. National Institutes of Health in Bethesda, Maryland. Combination therapy for hepatitis C; Management of chronic hepatitis C; Genetic aspects of the condition.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics